Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

178 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-02-28

Study Completion Date

2015-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective, observational study in a university hospital (UZ Leuven). Patients are included when they are treated with a potentional QT-prolonging drug: haloperidol for delirium, antibiotics (moxifloxacin, levofloxacin, azithromycin, clarithromycin, erythromycin, co-trimoxazole), antimycotics (ketoconazole, itraconazole, fluconazole, voriconazole), methadone, tacrolimus and oral oncolytics.

An ECG is taken before the administration of the drug and 3-5 days after starting the drug to investigate the change in duration of the QTc-interval. Risk factors for developing QT-prolongation will be documented. Together with ECG2, an additional blood sample will be collected to measure the blood concentration of the drug.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Decision Support System and Patient Portal for Preventing Medication-related Falls in Older Patients

NCT05449470

Fall Fall Injury Fall Patients +5 more

UNKNOWN NA

Discontinuation of Long-term Medications in Older People Entering Nursing Home Care

NCT03501108

Polypharmacy Frail Elderly Syndrome Inappropriate Prescribing +1 more

UNKNOWN NA

Reducing Injuries From Medication-Related Falls Using Computerized Alerts for High Risk Patients

NCT00818285

Fall Related Injury Risk

COMPLETED NA

Reduction of Polypharmacy in Elderly People With Multiple Diseases

NCT05526963

Polypharmacy Multimorbidity

RECRUITING NA

Enhancing the Detection and Management of Adverse Drug Events in Nursing Homes

NCT01531088

Adverse Drug Events

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Delirium QT-prolongation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients treated with a potentional QT-prolonging drug

Haloperidol, azi/clari/erythromycin, levo/moxifloxacin, co-trimoxazole, vori/keto/flu/itraconazole, methadone, tacrolimus, sunitinib

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Haloperidol, azi/clari/erythromycin, levo/moxifloxacin, co-trimoxazole, vori/keto/flu/itraconazole, methadone, tacrolimus, sunitinib

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

haloperidol: Haldol, ATC-code: N05AD01 azithromycin: Zitromax, ATC-code: J01FA10 clarithromycin: Biclar, ATC-code: J01FA09 erythromycin: Erytroforte, ATC-code: J01FA01 levofloxacin: Tavanic, ATC-code: J01MA12 moxifloxacin: Avelox, ATC-code: J01MA14 co-trimoxazole: Bactrim, Eusaprim, ATC-code: J01EE01 voriconazole: Vfend, ATC-code: J02AC03 ketoconazole: Nizoral, ATC-code: J02AB02 fluconazole: Diflucan, ATC-code: J02AC01 itraconazole: Sporanox, ATC-code: J02AC02 methadone: ATC-code: N07BC02 tacrolimus: Prograft, Advagraft, ATC-code: L04AD02 sunitinib: Sutent, ATC-code: L01XE04